Startup profile · funding coverage

Mentari Therapeutics

Biotech developing anti-PACAP and anti-CGRP bispecific antibodies for migraine prevention.

Stage

growth

Status

private

Coverage

full

Why Mentari Therapeutics is interesting

Paragon spinout targeting complementary migraine pathways — a16z Bio + Health among backers in a $290M private placement ahead of a reverse merger with InMed (2026).

Key facts

Private placement (2026): ~$290M led by Fairmount; a16z Bio + Health among participants ahead of InMed merger (BioPharma Dive)
Follow-on placement (Jul 2026): $200M from Fairmount, Venrock Healthcare, Blackstone Multi-Asset, and others (SEC filing)
Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

Investors in our directory

Funds linked from Mentari Therapeutics's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz

Industries

Biotech & Life Sciences Healthtech

Industry hub pages are rolling out from our fund-derived baseline taxonomy.

Venture Capital Tracker